Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials

UCLA's Jonsson Comprehensive Cancer Center

UCLA's Jonsson Comprehensive Cancer Center
JCCC: A Comprehensive Cancer Center
JCCC Member Directory
Calendar
Contact Us
Map and Directions to JCCC
Social Media
Connect via Mobile
Privacy Practices
 
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Sara Hurvitz, M.D.
Sara Hurvitz, M.D.

Specialty:

Hematology/Oncology
Internal Medicine

General Information:

Gender:
Female
Language(s):
English

Affiliation(s):

Assistant Clinical Professor, Department of Medicine, Hematology/Oncology
Director, Hematology/Oncology Breast Cancer Program
Co-Director, Santa Monica-UCLA Outpatient Hematology/Oncology Practice
Medical Director, JCCC Clinical Research Unit
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Santa Monica - UCLA Medical Center and Orthopaedic Hospital
Ronald Reagan UCLA Medical Center
Saint John's Health Center

Education:

Fellowship:
Hematology/Oncology, UCLA School of Medicine, 2003 - 2006
Residency:
Chief Resident, Internal Medicine, UCLA School of Medicine, 2002 - 2003
Internal Medicine, UCLA School of Medicine, 2000 - 2002
Internship:
Internal Medicine, UCLA School of Medicine, 1999 - 2000
Medical Degree:
M.D., USC School of Medicine, 1999

Certification(s):

Medical Board Certification(s):
Internal Medicine, American Board of Internal Medicine, 2002
Medical Oncology, American Board of Internal Medicine, 2006
Hematology, American Board of Internal Medicine, 2006

Contact Information:

UCLA Hematology and Oncology Santa Monica:
(310) 829-5471 Information and patient appointments
(888) 662-8252 [(888) ONC-UCLA] Information and patient appointments
Email:
shurvitz@mednet.ucla.edu

Practice Information:

Clinical Interest(s):
Breast

Scientific Interest(s):

Dr. Sara Hurvitz is interested in designing and implementing phase I and II (translational) breast cancer clinical trials. She is particularly interested in the development and testing of new targeted therapies for the treatment of breast cancer.

Dr. Hurvitz is also interested in studying the gene expression patterns in a variety of breast cancer populations, and evaluating these patterns to detect new subtypes of breast cancer that may be more accurately targeted by novel therapies.

Selected Cancer-Related Publications:

Hurvitz SA, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Ryba N, Lin LS, Wang H, Glaspy J, Slamon DJ, Kabbinavar F. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). Clin Breast Cancer. 2010 Aug 1;10(4):307-12.

Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Tarek S, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA. Phase I study of everolimus plus weekly Paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol. 2010 Dec 1;28(34):5110-5. Epub 2010 Oct 25.

Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R, Erlichman C, Lowy I, Timmerman JM. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009 Oct 15;15(20):6446-53. Epub 2009 Oct 6.

Hurria A, Wong FL, Pal S, Chung CT, Bhatia S, Mortimer J, Somlo G, Hurvitz S, Villaluna D, Naeim A. Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists. Oncologist. 2009 Sep;14(9):883-90. Epub 2009 Sep 2.

Hurvitz SA, Finn RS. What's positive about 'triple-negative' breast cancer? Future Oncol. 2009 Sep;5(7):1015-25.

In the News: